Most malignancies have increased glycolysis for energy requirement of rapid cell proliferation, which is the basis for tumor imaging through glucose analog FDG (2-deoxy-2-fluoro-D-glucose) with positron emission tomography. One of significant characteristics of prostate cancer is slow glycolysis and low FDG avidity. Recent studies showed that prostate cancer is associated with changes of fatty acid metabolism. Several enzymes involved in the metabolism of fatty acids have been determined to be altered in prostate cancer relative to normal prostate, which is indicative of an enhanced b-oxidation pathway in prostate cancer. Increased fatty acid utilization in prostate cancer provides both ATP and acetyl-coenzyme A (CoA); subsequently, increased availability of acetyl-CoA makes acceleration of citrate oxidation possible, which is an important energy source as well. Dominant fatty acid metabolism rather than glycolysis has the potential to be the basis for imaging diagnosis and targeted treatment of prostate cancer.
Introduction
Metabolic changes during malignant transformation have been noted for many years. Warburg 1 first reported that cancer cells preferentially rely on glycolysis as a major bioenergetic source even in the presence of oxygen and produce high levels of lactate and pyruvate. Glycolysis is a metabolic pathway by which glucose is converted to pyruvate with the generation of 2 molecules of ATP per molecule of glucose. Most non-dividing normal tissue, such as muscle, fully oxidize private formed from glycolysis to carbon dioxide and water in the mitochondrion with production of 38 molecules of ATP per molecule of glucose. These normal tissues generally do not convert glucose to lactic acid except when starved of oxygen. In contrast, tumors are characterized by converting much of glucose into lactic acid with sacrificing energy availability even in the presence of oxygen. The rate at which tumors convert glucose to lactic acid via glycolysis is generally correlated with their rate of proliferation and degree of aggressiveness. 2 Increased glucose consumption is a basic characteristic of malignant cells and is linked to energy production from glycolysis. Amplified glucose usage by malignant cells forms the theoretic basis for cancer detection through uptake of the glucose analog, fluorine-18-labeled 2-deoxy-2-fluoro-D-glucose (F18-FDG) with positron emission tomography (PET). Today, FDG-PET has been widely used for diagnosis, staging, restaging and monitoring therapy of various kinds of malignant diseases.
Glucose uptake across the plasma membrane is considered the rate-limiting step for glucose consumption in cells. 3 Transport of polar glucose across the nonpolar plasma membrane relies on glucose transporter protein, known as GLUTs. The previous study showed that there are increased GLUT expression in the membrane of the malignant cells compared to normal cells, which may be a key step for subsequent tissue FDG accumulation. 4, 5 Among total 13 members of facilitative GLUTs, cellular F18-FDG uptake is predominantly related to expression of GLUT1. 6, 7 Prostate cancer remains a major concern of public health. It is the most prevalent cancer in human beings and the second leading cause of male cancer death in the US. FDG-PET has not been very helpful in staging or detection of recurrence of prostate cancer because of low glycolysis. Clinical trial showed that FDG accumulation does not correlate with increasing grade or stage of the tumor and there is a significant overlap in FDG uptake between benign prostate hyperplasia and prostate cancer. 8, 9 Recent study revealed that GLUT1 mRNA and protein were only very weakly expressed in human prostate cancer tissue, which is considered to account for low FDG avidity of prostate cancer. 10 In vitro study also suggested that glucose may not be required for androgen-dependent prostate cancer cells because LNCaP cells can grow at control rates even in the presence of only 0.05 g/l glucose. 11 As rapid cell proliferation in malignant tumors is associated with increased energy supply, if glucose consumption is not elevated in prostate cancer, alterative metabolic approach, especially fatty acid oxidation may exist dominantly to provide bioenergy for abnormal cells proliferation and growth.
Changes of fatty acid metabolism in prostate cancer
Early observation suggested that in addition to the striking changes of glucose metabolism in human cancer, there is often also an increase in free fatty acid turnover, oxidation and clearance. 12, 13 The most recent study showed that a lipid mobilizing factor produced by the pancreatic tumor cells appears to be responsible for the increase in whole body fatty acid oxidation.
14 Recent studies revealed that prostate cancer is associated with changes of fatty acid metabolism. Several proteins involved in the metabolism of fatty acids have been determined to be altered in neoplastic prostate cells relative to their normal counterparts.
(1) Fatty acid metabolism represents a key process that influences several diverse cellular pathways and characteristics including cell signaling, energy processing and membrane fluidity. 15, 16 Fatty acid synthase (FAS) is considered to be a possible metabolic oncogene in prostate cancer. 17 Fatty acid synthase is overexpressed at both protein and mRNA levels in prostate cancer. 18, 19 Its high expression has also been associated with aggressive biologic behavior. 18 Interestingly, the highest levels of FAS expression are found in androgen-independent bone metastases. 19 Although it is possible that synthesis of fatty acids is required for the biogenesis of cellular membranes in rapidly dividing tumor cells, the simultaneous synthesis and breakdown of fatty acid is another explanation, which provides an energy source as a futile cycle in prostate cancer. The inhibition of FAS activity induces cell death in FAS-overexpressing cancer cell lines and prolongs survival of host animals implanted with tumor xenografts. [20] [21] [22] (2) Loss of stearoyl-CoA desaturase (SCD) expression is a frequent event in prostate cancer. 23 Stearoyl-CoA desaturase encodes a key rate-limiting enzyme involved in the synthesis of monounsaturated fatty acids. There was a significant reduction or complete lack of SCD transcripts and protein expression in human prostate cancer samples relative to benign epithelium. 23 Based on Ntambi's observation, the expression of several genes involved in the oxidation of lipids was upregulated, whereas lipid synthesis genes were downregulated; therefore, consequence of SCD deficiency is an activation of lipid oxidation in addition to reduced triglyceride synthesis and storage. 24 In the metabolite pool, loss of SCD expression would be expected to increase cellular palmitate level. 23 Further enhancement of the palmitate pool in neoplastic prostate epithelium would also result from overexpression of the fatty acid synthesis enzyme as described above. 25 In prostate cancer, increased expression of FAS and decreased expression of SCD would produce increasing level of palmitate, 23 which further drives fatty acid oxidation.
(3) b-Oxidation is the most prominent oxidation reaction for fatty acids and occurs both in the peroxisome and in the mitochondrion in higher eucaryotes. In contrast to mitochondrial b-oxidation, peroxisomal b-oxidation does not contribute to energy production directly, but is required for the initial oxidation of very long chain fatty acids, branched chain fatty acids, bile acid intermediates and other fatty acid derivatives, which cannot be directly oxidized by the mitochondrion. There are two separate b-oxidation pathways in the peroxisome: the classical peroxisome proliferators-inducible pathway and non-inducible pathway composed of branched chain acyl-CoA oxidase (ACOX2) and/or pristanoyl-CoA oxidase (ACOX3), D-bifunctional protein (DBP), and sterol carrier protein X. 26, 27 Recent study in vitro by Zha et al. 28 showed that there is increased expression of mRNA, protein and accompanied enzymatic activity of DBP in prostate cancer. Furthermore, their data suggested that ACOX3 is expressed in significant level, which might contribute to peroxisomal branched chain fatty acid b-oxidation in human prostate cancer. The study implied that increased peroxisomal branched chain fatty acid b-oxidation might provide unique metabolic pathway for prostate transformation.
(4) There is some striking direct evidence of increased fatty acid oxidation in prostate cancer recently. a-Methylacyl-CoA racemase (AMACR) is a peroxisomal and mitochondrial enzyme involved in the b-oxidation of branched fatty acid. Both in the peroxisome and the mitochondrion, AMACR is required to catalyze the interconversion of the R-and S-isomers, which is necessary before oxidation can proceed. Multiple studies revealed the consistent and specific overexpression of AMACR in prostate cancer versus normal prostate. [29] [30] [31] [32] Sequence variants of AMACR have been linked to prostate cancer risk. a-Methylacyl-CoA racemase enzymatic activity is consistently elevated in prostate cancer tissue specimen. 32 All these are indicative of an enhanced b-oxidative pathway in prostate cancer, which provides ATP as an energy source.
Fatty acid metabolism and citrate oxidation in prostate cancer
It is known that increased citrate oxidation is a significant metabolic characteristic for the bioenergy requirement in prostate cancer. The normal human prostate gland, as well as that of many other animals, has the function of producing, accumulating and ultimately secreting extraordinarily high levels of citrate. 33, 34 In contrast to the high citrate levels associated with normal prostate tissue and benign hyperplasia, prostate cancer is characterized by a low level of citrate, which is a basis of magnetic resonance spectroscopy (MRS) for in situ detection of prostate cancer. 35, 36 Magnetic resonance spectroscopy measures change of level of citrate in the form of choline/citrate for detection and localization of prostate cancer.
The early report demonstrated that the decrease in citrate levels was evident early in prostate malignancy and preceded the histopathologic identification of 37 The recent studies showed that activity of mitochondrial (m)-aconitase, the first reaction before citrate oxidation, is significantly higher in prostate cancer compared to normal prostate, which drives the utilization of citrate as energy source. 38 Based on bioenergetics of prostate epithelial cell metabolism, Costello and Franklin proposed 'bioenergetic theory of prostate malignancy': the transformation of a citrate-producing sane epithelial cell to a malignant citrate-oxidating cell would result in a more efficient energy-generating system. To meet the energetic requirements of malignant cells, the metabolic transformation into citrate oxidation must be an early event in preparation for the progression of malignancy. 39 Net citrate production requires the continuous availability of oxaloacetate and acetyl-CoA for continuous citrate synthesis. Acetyl-coenzyme A is an only molecule consumed in citrate cycle and its continuous availability is crucial for driving citrate oxidation. Typically, phosphofructokinase, a key enzyme in regulation of glycolysis in cell metabolism, is inhibited by citrate, which also account for slow glycolysis in addition to low GLUTs on the cell membrane in prostate cancer. Because of limited availability of acetyl-CoA from slow glycolysis, fatty acid oxidation is the only alternative source which cannot be dismissed ( Figure 1 ).
Illustration demonstrates relationship between citrate production/oxidation and fatty acid pathway.
Diet fat and prostate cancer
There is existing evidence for an association between dietary fat consumption and prostate cancer. The recent meta-analysis of all 13 published case-control and cohort studies demonstrated a statistically significant association for dietary fat and prostate cancer. 40 Animal data also added credence to the concept of dietary fat as a promoter of prostate cancer, independent of total energy and body mass index. 41, 42 There are many possible associations between dietary fat intake and risk of prostate cancer, the most significant is that dietary fat may change androgen milieu. 40 Hill et al. 43 reported that urinary androgen levels decreased in blacks and white males who reduced fatty intake. Dorgen et al. 44 performed a randomized crossover study of high-and low-fat dietary intervention in which levels of total and free testosterone were increased when men consumed a higher fat diet. Additional mechanisms to explain an association between dietary fat and prostate cancer are free radicals and proinflammatory fatty acid metabolites such as specific leukotrienes and prostaglandins produced by dietary fat. 45 In addition, dietary fat may impact serum insulin-like growth factor level, 46 which is considered to be associated with development and progression of many malignancies. It is believed that a reduction in fat consumption would result in reduction in prostate cancer incidence. 47, 48 Figure 1 Citrate metabolism and fatty acid pathway. Fats are broken down to fatty acids and glycerol. Fatty acids are oxidized to acetylcoenzyme A (CoA), which enters the tricarboxylic acid cycle (TCA) cycle for ATP production and energy. The acetyl-CoA is supplied by glycolysis or/and fatty acid oxidation.
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Conclusion
Prostate cancer is characterized by low glycolysis. The recent studies suggested that there are changes of fatty acid metabolism in prostate cancer. To meet the bioenergetic requirement for rapid cell proliferation in prostate cancer, there is elevated fatty acid oxidation that provides both ATP and acetyl-CoA; subsequently, increased availability of acetyl-CoA makes acceleration of citrate oxidation possible, which is also an important energy source. Fatty acid oxidation as a dominant bioenergetic pathway has the potential to be the basis for drug targeting and diagnostic imaging in prostate cancer, for example, a new PET tracer C11-acetate, which measures oxidative metabolism of fatty acids, has shown promising results on clinical trials and were more sensitive than FDG-PET in both primary and metastatic prostate lesions. 49, 50 
